

EXONHIT RECEIVES € 1.93 MILLION FROM OSEO WITHIN THE PERSONALIZED MEDICINE TEDAC PROJECT IN CANCER

- Financing of € 1,928,000 through both grants and redeemable advances
- Identification of susceptibility to therapeutic response biomarkers
- Development of a companion diagnostic

Paris, France – June 5, 2012 – Exonhit (Alternext: ALEHT) announced today that it has been granted € 1,928,000 by OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for "Strategic Industrial Innovation". € 1,126,000 were paid to Exonhit at the inception of the project during the first semester of 2012.

Headed by project leader ERYTECH Pharma, the consortium includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radio-resistant cancers, and tools enabling personalized care of patients. This project, endorsed by the Competitiveness Cluster Lyonbiopôle, will last 8 years. The total amount awarded to the consortium amounts to approximately €10.7 million.

Exonhit was selected to participate in both phases of the project by using its proprietary Genome Wide SpliceArray™ (GWSA) technology, to study tumor transcriptomic profiles in the initial phase, followed by the use of its capabilities in diagnostic test development to translate these profiles into a companion diagnostic.

The Company will be responsible for:

- 1) the identification of biomarkers of susceptibility to therapeutic response in the context of reducing the risks associated with the development of treatments, and
- 2) the development of an enzymatic therapy companion diagnostic that will identify responders, thus improving personalized care.

"This project is a new opportunity for the Company to implement its expertise in the development of companion diagnostics, and a key step in the implementation of our strategy in personalized medicine," said Loïc Maurel, CEO of Exonhit. "The financial support of OSEO will also enable us to move towards solutions better adapted to the commercialization of diagnostics developed using our GWSA technology."

About the "Strategic Industrial Innovation" Program from OSEO

The "Strategic Industrial Innovation" (ISI) program promotes the emergence of European champions. It supports ambitious collaborative industry-oriented innovations, implemented by academic institutions together with medium-sized companies (less than 5,000 employees) and SMEs (less than 250). If successful, these projects are very promising: they aim at commercializing products and technological breakthroughs that could not be achieved without public funding. The financial aid ranges from € 3 to 10 million in the form of grants and redeemable advances.

About Exonhit's GWSA platform

Exonhit's Genome Wide SpliceArray™ (GWSA) platform is a patented microarray design that incorporates a specific probe configuration, enabling an exhaustive monitoring of RNA splice variants in humans, mice and rats. These arrays cover whole genomes and monitor known and predicted alternative RNA splicing events. They are used in the Company's biomarker and target discovery process.

About Exonhit

Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer's disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations.

Exonhit is headquartered in Paris, France and has a U.S. subsidiary in Gaithersburg, Maryland. The Company is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

About ERYTECH Pharma

ERYTECH Pharma is a biopharmaceutical company specializing in the development and production of pharmaceutical drugs in oncology. Its patented technology is based on the use of human red blood cells to improve the pharmacokinetic and pharmacodynamic properties of therapeutic enzymes (eg L-asparaginase).

Its lead product, GRASPA®, an orphan drug in Europe and the U.S., is indicated for the treatment of acute lymphoblastic leukemia and is currently undergoing a phase II / III pivotal clinical trial. ERYTECH has implemented a manufacturing unit for the cGMP production of clinical batches. For further information, visit <http://www.erytech.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Hervé Duchesne de Lamotte
CFO
+33 1 53 94 52 49
herve.delamotte@exonhit.com

ACTIFIN
Nicolas Meunier/Alexandre Commerot
+ 33 1 56 88 11 11
acommerot@actifin.fr